肿瘤细胞治疗研究
英文原题：Challenges and Emerging Strategies of Immunotherapy for Glioblastoma.
胶质母细胞瘤（GBM）被认为是中枢神经系统最致命的原发性恶性肿瘤。
胶质母细胞瘤（GBM）被认为是中枢神经系统最致命的原发性恶性肿瘤。尽管传统治疗可以在一定程度上延长患者生存期，但总体预后仍然严峻。免疫治疗已成为GBM治疗的有效方法。溶瘤病毒、检查点抑制剂、CAR T细胞和肿瘤疫苗均已应用于该领域。此外，免疫治疗与传统放疗、化疗或基因治疗的联合可以进一步提高治疗效果。本综述系统总结了GBM的特征、免疫治疗在克服GBM方面的最新进展。
Glioblastoma (GBM) is recognized as the most lethal primary malignant tumor of the central nervous system. Although traditional treatments can somewhat prolong patient survival, the overall prognosis remains grim. Immunotherapy has become an effective method for GBM treatment. Oncolytic virus, checkpoint inhibitors, CAR T cells and tumor vaccines have all been applied in this field. Moreover, the combining of immunotherapy with traditional radiotherapy, chemotherapy, or gene therapy can further improve the treatment outcome. This review systematically summarizes the features of GBM, the recent progress of immunotherapy in overcoming GBM.
MEMBER ACCOUNT
登录成功会直接打开下一页。
